Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of BIIB074 for neuropathic pain from lumbosacral radiculopathy
NL-OMON42982Phase 2Withdrawn
- Sponsor
- Convergence Pharmaceuticals
- Start
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vixotrigine in Neuralgia, sponsored by Convergence Pharmaceuticals. Primary endpoints: Adverse events and serious adverse events, Vital signs and 3 more. Planned start Dec 2016; status: withdrawn.
02
Drugs
vixotrigine
03
Conditions
Neuralgia
Beyond the preview
Go deeper on NL-OMON42982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42982.